Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis

We herein report a 42-year-old man with advanced lung adenocarcinoma and nivolumab-associated dermatomyositis. Nivolumab, an anticancer drug that is classified as an immune checkpoint inhibitor, often induces immune-related adverse events (irAEs). However, there have so far been no reports regarding...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Intern Med
Auteurs principaux: Kudo, Fumiaki, Watanabe, Yasutaka, Iwai, Yuki, Miwa, Chihiro, Nagai, Yoshiaki, Ota, Hiromitsu, Yabe, Hiroki, Demitsu, Toshio, Hagiwara, Koichi, Koyama, Nobuyuki, Koyama, Shinichiro
Format: Artigo
Langue:Inglês
Publié: The Japanese Society of Internal Medicine 2018
Sujets:
Case Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6120830/
https://ncbi.nlm.nih.gov/pubmed/29526968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.9381-17
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires